{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"64.6","upperLimit":"98.5","value":"81.6"},{"comment":"NA indicates that the upper limit of confidence interval was not estimable due to insufficient number of participants with events.","groupId":"OG001","lowerLimit":"52.5","upperLimit":"NA","value":"80.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"231"},{"groupId":"OG001","value":"100"}],"units":"Participants"}],"description":"OS is defined as the time from the date of randomization until death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Vandetanib (300 mg daily)","id":"OG000","title":"Vandetanib 300 mg"},{"description":"Placebo daily","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From date of randomization until death, up to approximately 105 months","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}